ATE466590T1 - Promotor der proliferation und inhibitor der apoptose pankreatischer langerhans beta-zellen und screening von anwärter-verbindungen für medikamente - Google Patents
Promotor der proliferation und inhibitor der apoptose pankreatischer langerhans beta-zellen und screening von anwärter-verbindungen für medikamenteInfo
- Publication number
- ATE466590T1 ATE466590T1 AT01934500T AT01934500T ATE466590T1 AT E466590 T1 ATE466590 T1 AT E466590T1 AT 01934500 T AT01934500 T AT 01934500T AT 01934500 T AT01934500 T AT 01934500T AT E466590 T1 ATE466590 T1 AT E466590T1
- Authority
- AT
- Austria
- Prior art keywords
- expression
- gene
- screening
- cells
- beta cells
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000012216 screening Methods 0.000 title abstract 3
- 230000035755 proliferation Effects 0.000 title abstract 2
- 108091007065 BIRCs Proteins 0.000 title 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 101150022655 HGF gene Proteins 0.000 abstract 2
- 108090001005 Interleukin-6 Proteins 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract 2
- 239000003862 glucocorticoid Substances 0.000 abstract 2
- 230000006698 induction Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 abstract 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 abstract 1
- 102100026019 Interleukin-6 Human genes 0.000 abstract 1
- 239000012661 PARP inhibitor Substances 0.000 abstract 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/507—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000170447 | 2000-06-02 | ||
| JP2001054072 | 2001-02-28 | ||
| PCT/JP2001/004660 WO2001093899A1 (en) | 2000-06-02 | 2001-06-01 | PANCREATIC LANGERHANS β CELL PROLIFERATION PROMOTER AND APOPTOSIS INHIBITOR, AND SCREENING OF CANDIDATE COMPOUNDS FOR THE E DRUGS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE466590T1 true ATE466590T1 (de) | 2010-05-15 |
Family
ID=26593476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01934500T ATE466590T1 (de) | 2000-06-02 | 2001-06-01 | Promotor der proliferation und inhibitor der apoptose pankreatischer langerhans beta-zellen und screening von anwärter-verbindungen für medikamente |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040091453A1 (de) |
| EP (1) | EP1297841B1 (de) |
| AT (1) | ATE466590T1 (de) |
| AU (2) | AU2001260696B2 (de) |
| CA (1) | CA2410918A1 (de) |
| DE (1) | DE60142050D1 (de) |
| WO (1) | WO2001093899A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050115874A (ko) * | 2003-03-03 | 2005-12-08 | 산에이겐 에후.에후. 아이. 가부시키가이샤 | 아디포넥틴 발현촉진제 |
| JP2008513435A (ja) * | 2004-09-22 | 2008-05-01 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物 |
| WO2015067744A1 (en) * | 2013-11-07 | 2015-05-14 | Vrije Universiteit Brussel | Screening assay for agents that influence beta cell number and/or phenotype |
| IT201800000534A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
| GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648597A (en) * | 1990-04-20 | 1997-07-15 | University Of South Carolina | Alpha-1-acid glycoprotein transgenic mice |
| DE69133492T2 (de) * | 1990-06-11 | 2006-08-10 | Nakamura, Toshikazu | Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung |
| JP3570557B2 (ja) * | 1992-12-01 | 2004-09-29 | 塩野義製薬株式会社 | ｒｅｇタンパク質を有効成分とする薬剤 |
| US6001647A (en) * | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
| ES2240999T3 (es) * | 1995-08-29 | 2005-10-16 | Anges Mg, Inc. | Medicamento que contiene un gen del hgf. |
| AU7443996A (en) * | 1995-10-30 | 1997-05-22 | Vivorx, Inc. | Method for ex vivo proliferation and differentiation of adult pancreatic islet cells, media useful therefor and uses thereof |
| US6391312B1 (en) * | 1997-01-23 | 2002-05-21 | Sumitomo Pharmaceuticals Co., Limited | Remedies for diabetes |
| JP4006058B2 (ja) * | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び／又は治療剤 |
| WO1999020740A2 (en) * | 1997-10-23 | 1999-04-29 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
| WO1999046371A2 (en) * | 1998-03-11 | 1999-09-16 | Board Of Regents, The University Of Texas System | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| US6326201B1 (en) * | 1999-02-10 | 2001-12-04 | Curis, Inc. | Pancreatic progenitor cells, methods and uses related thereto |
-
2001
- 2001-06-01 AT AT01934500T patent/ATE466590T1/de not_active IP Right Cessation
- 2001-06-01 WO PCT/JP2001/004660 patent/WO2001093899A1/ja not_active Ceased
- 2001-06-01 EP EP01934500A patent/EP1297841B1/de not_active Expired - Lifetime
- 2001-06-01 AU AU2001260696A patent/AU2001260696B2/en not_active Ceased
- 2001-06-01 AU AU6069601A patent/AU6069601A/xx active Pending
- 2001-06-01 US US10/297,058 patent/US20040091453A1/en not_active Abandoned
- 2001-06-01 DE DE60142050T patent/DE60142050D1/de not_active Expired - Fee Related
- 2001-06-01 CA CA002410918A patent/CA2410918A1/en not_active Abandoned
-
2005
- 2005-11-21 US US11/284,489 patent/US20060134063A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040091453A1 (en) | 2004-05-13 |
| AU6069601A (en) | 2001-12-17 |
| DE60142050D1 (de) | 2010-06-17 |
| EP1297841A4 (de) | 2006-06-28 |
| CA2410918A1 (en) | 2002-11-29 |
| AU2001260696B2 (en) | 2005-04-14 |
| EP1297841B1 (de) | 2010-05-05 |
| US20060134063A1 (en) | 2006-06-22 |
| WO2001093899A1 (en) | 2001-12-13 |
| EP1297841A1 (de) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haque et al. | CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein (a) in human vascular endothelial cells | |
| Quintás-Cardama et al. | Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis | |
| Kranzhofer et al. | Expression of tissue inhibitor of metalloproteinase-1,-2, and-3 during neointima formation in organ cultures of human saphenous vein | |
| Ong et al. | PAF promotes stemness and radioresistance of glioma stem cells | |
| DeLoughery et al. | DNA double-strand breaks by Cr (VI) are targeted to euchromatin and cause ATR-dependent phosphorylation of histone H2AX and its ubiquitination | |
| Bogliolo et al. | The Fanconi anaemia genome stability and tumour suppressor network | |
| Sall et al. | Dibasic benzo [b] thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure− activity relationships, and binding orientation | |
| Richters et al. | Identification and further development of potent TBK1 inhibitors | |
| Debret et al. | Elastin-derived peptides induce a T-helper type 1 polarization of human blood lymphocytes | |
| Koopman et al. | Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor | |
| Dumler et al. | Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells | |
| Ali et al. | Matrix metalloproteinase‐2 mediates ribosomal RNA transcription by cleaving nucleolar histones | |
| Waldeck et al. | CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML | |
| Moe et al. | Tumor necrosis factor-α induces aortic intima-media thickening via perivascular adipose tissue inflammation | |
| Rauch et al. | Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions | |
| Chesnokova et al. | GH and senescence: a new understanding of adult GH action | |
| Zoller et al. | Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio | |
| Kushwaha et al. | Rosiglitazone up‐regulates glial fibrillary acidic protein via HB‐EGF secreted from astrocytes and neurons through PPARγ pathway and reduces apoptosis in high‐fat diet‐fed mice | |
| Gunawardana et al. | Cadmium inhibits both intrinsic and extrinsic apoptotic pathways in renal mesangial cells | |
| DE60142050D1 (de) | Promotor der proliferation und inhibitor der apoptose pankreatischer langerhans beta-zellen und screening von anwärter-verbindungen für medikamente | |
| Granofszky et al. | Identification of PMN-released mutagenic factors in a co-culture model for colitis-associated cancer | |
| Yao et al. | Novel flavonoids with anti-proliferative activities against breast cancer cells | |
| Knüpfer et al. | CYP2C and IL-6 expression in breast cancer | |
| Kanatani et al. | Transforming growth factor beta and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of human monocytoid leukemia cells. | |
| Kalita et al. | IGF‐1 stimulated upregulation of cyclin D1 is mediated via STAT5 signaling pathway in neuronal cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |